Seeking Alpha
10 Nov 2026, 16:49 UTC · 1d ago
Impact · against what's priced in
The article is a non-event for CGEN and AZN as it merely confirms known clinical timelines and cash positions. The expected Q1 2027 data for COM701 and the phase 3 trials for rilvegostomig are already the primary drivers of current valuations.
No priced-in read yet
What the story claims
3 claims · scored −1 bearish … +1 bullish · 0 new · 3 priced in
COM701 phase 1/2 MAIA-ovarian trial results for relapsed PSOC are expected in Q1 2027.
Priced inanalysis of clinical programs in an opinion piece
So whatPositive data in Q1 2027 would validate the lead asset's efficacy in a high-unmet-need market, likely triggering a significant valuation re-rating.
More positive than 93% of claims this week
Rilvegostomig is currently in 12 ongoing phase 3 trials across multiple solid tumors with key data expected in 2027.
Continue reading
5 related stories
The mention of 12 ongoing phase 3 trials for rilvegostomig is a continuation of known strategic developments and does not alter the stock's current trajectory.
Read from the article alone
No priced-in read yet
The confirmation that COM701 results are on track for Q1 2027 and the $117.5M cash balance are already reflected in the current valuation and prior analysis.
Read from the article alone
Scored by the NIS engine · methodology.
Search tags
Priced inanalysis of clinical programs in an opinion piece
More positive than 85% of claims this week
Compugen held $117.5M in cash as of Q3 2026.
Priced inrefers to Q3 2026 data
So whatCurrent funding supports operations into 2029, implying no need for equity dilution to fund the 2027 catalysts.
More positive than 64% of claims this week
Which stocks this story touches
More positive than 89% of ticker scores this week
The company maintains a 'Buy' rating due to advancing clinical programs, strong capitalization, and a strategic partnership with AstraZeneca.
More positive than 63% of ticker scores this week
Positive mention regarding its ongoing phase 3 trials leveraging Compugen's TIGIT component.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
10h ago
−2.6%
$184.50 vs $189.39 close before publication (Nov 9) · not market-adjusted
AZN chart →−2.1%
$2.10 vs $2.14 close before publication (Nov 9) · not market-adjusted
CGEN chart →
